Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis.

BMC Cancer · 2019 · PMC6466705 · PMID 30987609

Europe PMC DOI

hedged sentence

0.0508

closest p · 1.0× alpha

0.0508

boldest claim

The sentences

borderline significanceP = 0.0508so close (0.05 < p ≤ 0.1)

For PFS, only docetaxel plus ramucirumab gave a significant benefit, of 1.2 months, in mean survival, and nivolumab showed borderline significance ( P = 0.0508) with 2.6 months (Additional file 1 : Figures S10–S12).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.